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Strengths and limitations of this study
 ► This is the first study to explore patient data link-
age to investigate the association of a postdischarge 
intervention in community pharmacy with hospital 
readmissions.
 ► Pseudonymised data were made identifiable and 
linked across multiple national databases.
 ► The data linkage failed to record patients’ access of 
any other healthcare services, such as the general 
practitioner, following discharge.
 ► Even though this was a retrospective observation-
al cohort study, we addressed potential for bias by 
confounder adjusted analysis.
 ► No investigation was carried out in this study on the 
barriers and facilitators of activation of discharge 
medicines review part 1, via an implementation sci-
ence lens.
AbStrACt
Objective To evaluate the association of the discharge 
medicines review (DMR) community pharmacy service 
with hospital readmissions through linking National Health 
Service data sets.
Design Retrospective cohort study.
Setting All hospitals and 703 community pharmacies 
across Wales.
Participants Inpatients meeting the referral criteria for a 
community pharmacy DMR.
Interventions Information related to the patient’s 
medication and hospital stay is provided to the community 
pharmacists on discharge from hospital, who undertake 
a two- part service involving medicines reconciliation and 
a medicine use review. To investigate the association of 
this DMR service with hospital readmission, a data linking 
process was undertaken across six national databases.
Primary outcome Rate of hospital readmission within 90 
days for patients with and without a DMR part 1 started.
Secondary outcome Strength of association of age 
decile, sex, deprivation decile, diagnostic grouping 
and DMR type (started or not started) with reduction in 
readmission within 90 days.
results 1923 patients were referred for a DMR over a 
13- month period (February 2017–April 2018). Provision 
of DMR was found to be the most significant attributing 
factor to reducing likelihood of 90- day readmission using 
χ2 testing and classification methods. Cox regression 
survival analysis demonstrated that those receiving the 
intervention had a lower hospital readmission rate at 40 
days (p<0.000, HR: 0.59739, CI 0.5043 to 0.7076).
Conclusions DMR after a hospital discharge is associated 
with a reduction in risk of hospital readmission within 40 
days. Linking data across disparate national data records 
is feasible but requires a complex processual architecture. 
There is a significant value for integrated informatics to 
improve continuity and coherency of care, and also to 
facilitate service optimisation, evaluation and evidenced- 
based practice.
IntrODuCtIOn
It is widely acknowledged that medicines- 
related errors and adverse events can occur 
at points of patients transitioning between 
healthcare settings.1–4 Internationally, 
numerous interventions have been designed 
and delivered to try and address this even-
tuality, with the aim to reduce medicines- 
related, preventable hospital readmissions. A 
recent systematic review has found that inter-
ventions involving a community pharmacist 
after hospital patients are discharged home, 
demonstrate capacity to identify and rectify 
medicine- related problems, which could have 
resulted in avoidable hospital admission.5 
In June 2019, the National Health Service 
(NHS) in England committed to introduce 
a postdischarge medicines reconciliation 
service through community pharmacies by 
2024.6
Currently in the UK there are three main 
transfer- of- care technologies or services, 
whereby community pharmacists contribute 
to the medicines reconciliation process 
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posthospital discharge: (1) Refer- to- Pharmacy, an online 
platform adopted in East Lancashire that refers patients 
along with discharge information from hospital for post-
discharge medicines support through the community 
pharmacy, as judged appropriate by the community phar-
macist, for example, targeted medicine use reviews7 8; (2) 
PharmOutcomes, an online portal widely used in commu-
nity pharmacies across England that allows hospitals to 
upload discharge information, which can then be trans-
mitted and accessed by community pharmacists to provide 
postdischarge support services9 10; and (3) discharge 
medicines review (DMR) service, used across Wales, 
which integrates the referral of patient hospital discharge 
information to community pharmacies with a two- stage 
service including identifying discrepancies between the 
first prescription postdischarge and the discharge advice 
letter, followed up by a supportive medication review 
focused on adherence.11
A service evaluation in 2016 aimed to assess if a new 
transfer- of- care service implemented from hospitals 
in the North East of England that involved patients 
being referred to a nominated community pharmacy 
on discharge for follow- up care led to reduced hospital 
readmissions.9 Patient referrals in the hospital were 
generated using PharmOutcomes; hospital pharmacy staff 
were required to input patient data since there was no 
interconnectivity with the electronic NHS patient record 
at that time. Community pharmacy staff were then 
completing intervention and outcome data on the Phar-
mOutcomes platform. The evaluation showed that this 
service was associated with significantly reduced patient 
readmissions to hospital in 30, 60 and 90 days and shorter 
length of hospital stay if they were readmitted.9 However, 
PharmOutcomes is not used nationally across England, and 
outcome data completed by community pharmacists were 
not networked back to the hospital where the referral 
was generated. Due to this disjointed information flow, 
retrieving data about subsequent hospital readmissions 
and length of hospital stays required access of another 
database with steps of deanonymisation and reanonymi-
sation to match data in PharmOutcomes with data in the 
hospital admission records.
The DMR service is a two- part, community pharma-
cist- led service introduced in Wales in 2011 to support 
patients with their transition from one care setting to 
another. The service has mainly been used for patients 
recently discharged from hospital and transitioning 
back into the home environment.11 The aim, as with the 
transfer- of- care service in the North East, is to reduce the 
risk of preventable medicines- related problems, improve 
adherence with newly prescribed medicines, and improve 
patient knowledge and use of medicines. This service 
is operationalised employing electronic platforms and 
developed interoperability to generate a referral from 
the hospital to a nominated community pharmacy. Part 
1 of the service is a medicines reconciliation between 
the medications listed in the first prescription from 
the general practitioner (GP) after discharge and the 
discharge medication list, including rectifying any unin-
tended discrepancies that have arisen. The rectification of 
these discrepancies may involve contact with the patient 
or carer, GP or the hospital to gather the most relevant 
information. Part 2 is a medicines use review that gives 
the pharmacist an opportunity to discuss any medicines- 
related issues with the patients, including adherence, 
dosing and side effects. Evaluation of the DMR service 
has shown positive outcomes, including the identifica-
tion of 1.15–1.3 discrepancies per service completed 
and an average threefold return on financial invest-
ment.12 13 After the initial evaluation confirmed the bene-
fits of the service,12 it was rolled out nationally, currently 
being available in 703 community pharmacies in Wales. 
The evaluations focused on cost benefit and identifying 
discrepancies in the medicines’ reconciliation process. 
However, to date, there has been no formal process of 
linking data from the DMR service to hospital data with 
a subsequent evaluation of the association of DMR with 
patient readmission to hospital.
Linking data sets from different divisions in the NHS 
has been reported to be limited, and it is widely acknowl-
edged that NHS data are not used effectively to guide 
patient care.14 The aim of this study was to explore the 
use of national routine data linkage to investigate the 
association of DMR with patient hospital readmission.
MethODS
Intervention description
The independent evaluation undertaken in 2014 provides 
a description of the DMR service in Wales12; however, it is 
briefly outlined here to provide a contextual background.
Pharmacists in a total of 703 out of 716 community 
pharmacies in Wales are currently completing DMRs 
with the support of Choose Pharmacy, a national web- based 
application that supports the delivery of NHS advanced 
and enhanced community pharmacy services. Accredited 
community pharmacies and community pharmacists can 
access via Choose Pharmacy an electronic discharge advice 
letter (eDAL) generated by the medicines transcribing 
and electronic discharge (MTeD) functionality in the 
National Welsh Clinical Portal, to support an electronic 
DMR. Patients are linked to the Welsh Demographic 
Service and matched to existing health records, enabling 
collection of demographic information such as gender 
and age. When an eDAL is generated, the patient’s nomi-
nated community pharmacy receives a notification via the 
Electronic NHS Alert Service that one of their patients has 
been discharged from hospital. In the event a patient has 
been discharged from a non- MTeD ward and has received 
a paper discharge advice letter, a physical copy needs to 
be taken to the pharmacy for DMR to be initiated. Choose 
Pharmacy is still used to record the DMR undertaken.
Patients are identified and recruited to the DMR service 
either by referral from a healthcare professional during 
their hospital stay or following their discharge by patients 
self- referring, by their nominated carer presenting in the 
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Table 1 Description of the type of data collected and stored in the national databases in Wales that were used in the data 
linkage in this study
National data source in Wales Overview
Choose Pharmacy A national web- based application that supports the delivery of NHS advanced and enhanced 
community pharmacy services in Wales. Holds data for all services completed in the 
pharmacy in the form of clinical information and predefined answers, including data for all 
electronic DMRs that were completed using Choose Pharmacy.
Patient Episode Database for 
Wales
A system that records all episodes of inpatient and day case activity in NHS Wales hospitals, 
which include planned and emergency admissions, minor and major operations, and hospital 
stays for giving birth.
Admitted Patient Care Data Set Captures data for all consultant- led admitted patient activity, regardless of the patient’s area 
of residence. NHS Digital provides data on Welsh resident or registered patients treated in 
English NHS organisations.
Once admitted, a patient may have several episodes within a hospital stay. Only once an 
episode is complete or the hospital spell ends will it be captured in the Admitted Patient 
Care Data Set.
Office of National Statistics 
death notifications database
Annual data on deaths registered by age, sex and selected underlying cause of death.
Welsh Demographics Service Provides the demographic characteristics of people registered with GP practices in Wales. 
The Welsh Demographics Service maintains a register of Welsh residents’ demographic 
details, including name, address, date of birth, general practice and NHS number.
For any consultations completed via Choose Pharmacy, patients are linked to the Welsh 
Demographic Service and matched to existing health records, enabling collection of 
demographic information.
National Data Resource A resource currently being developed to better enable NHS Wales to improve patient 
experience and service outcomes. The National Data Resource aims to deliver a more 
joined- up approach to health and care data, using common language and technical 
standards and providing improved analytics capability.
DMRs, discharge medicines reviews; GP, general practitioner; NHS, National Health Service.
pharmacy or by the pharmacist when necessary criteria 
are met.
Patients are eligible for the service when the following 
criteria are met:
 ► The patient’s medicines have been changed during 
their hospital stay.
 ► The patient is taking four or more medicines.
 ► The patient’s medicine requires dispensing into a 
multicompartment compliance device.
 ► The pharmacist has, in their professional opinion, 
reason to consider that the patient would benefit 
from the service.
Outcome measures
The primary outcome in this study was the rate of 
hospital readmission within 90 days for patients with 
and without a DMR part 1 started. The secondary 
outcome was the strength of association of age decile, 
sex, deprivation decile, diagnostic grouping and DMR 
type (started or not started) with rate of readmission 
within 90 days.
routine data collection
Six data sources were used for this study, with data 
obtained via the NHS Wales Informatics Service (NWIS) 
for the period of February 2017–April 2018 (table 1).
Data linkage
Hospital data were available for all patients who were 
referred for the service on hospital discharge, selected by 
clinical staff based on one or more of the DMR criteria. 
The data linkage process was completed in three steps 
and ensured that pseudonymised data from individuals 
could be linked together to provide a picture of the 
patient’s journey without patient identifiable information 
being shared (figure 1):
 ► Step 1: extracting data for pseudonymisation: records 
for pseudonymisation were identified when a patient 
was referred from a hospital to a community phar-
macy for a DMR.
 ► Step 2: pseudonymising patient- specific pharmacy 
data: the pseudonymisation process involved the 
encryption of the patient’s NHS number to create an 
anonymous linking field (ALF), which was assigned to 
each record.
 ► Step 3: linking of pseudonymised pharmacy data to 
pseudonymised hospital data: the ALF was used to 
link these records to the pseudonymised identifiable 
patient records in hospitals, which have been assigned 
with the same ALF.
Information from these data sets was used to create 
a new data set for analysis, which included whether the 
pseudonymised patient had received the DMR service, 
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Figure 1 Information flow diagram depicting the architecture required to link all required patient data to investigate hospital 
readmission outcome data for those offered a DMR service. DMR, discharge medicines review; NDR, National Data Resource; 
PEDW, Patient Episode Database for Wales; SQL, Structured Query Language.
admission information such as their age, deprivation quin-
tile, diagnosis, length of stay before they were referred 
into the DMR service, and the same admission informa-
tion for the first admission occurring after referral to 
the DMR service. The full process for the data linkage is 
shown in online supplementary table 1.
ethical considerations
Data collection at the first instance was part of routine 
collection of information when the patient visits a health-
care setting. Patients provided informed consent when 
offered the DMR service as part of routine hospital and 
community pharmacy care. This consent covers the 
recording of data and any processing or preprocessing 
to a form (by NWIS), for the purpose of service activity, 
audit and evaluation, in an identifiable way. Records- 
based research was then completed that did not involve 
people directly.
The NWIS Head of Information Governance 
approved the methodology and helped set the criteria 
for processing the information to ensure patient privacy 
was maintained in all circumstances. The model of 
processing and data linkage was consistent with the 
NWIS trusted third- party responsibilities and is used in 
many circumstances to ensure confidentiality, integrity 
and availability of information, in line with guidance 
for use of secondary data and criteria set by the General 
Medical Council in relation to anonymisation and risk of 
de- identification.15 16
Data analysis
Secondary data analysis was conducted using Microsoft 
Excel for descriptive statistics and Stata Special Edition 
14.2 and R (using the partykit and survival libraries) for 
more complex statistical analyses. In order to ensure 
that there was sufficient time following referral to 
capture data about a patient being readmitted, all refer-
rals after 31 December 2017 (which is 90 days prior to 
the last date in the data extract) were removed from the 
data set. The denominator for the calculations was all 
inpatients referred for a DMR, the intervention group 
was those who activated part 1 of the DMR, and the 
comparator was those referred for a DMR but who did 
not activate it.
Pearson’s χ2 test, using a significance level of 0.05, was 
applied to records of all patients offered a DMR who 
did not die within 90 days of their discharge, to assess 
whether the DMR changed the probability of readmission 
and evaluate how likely it is that any observed difference 
between the sets arose by chance. The χ2 test has a null 
hypothesis that there is no association between whether 
a patient had started a DMR (had completed at least 
part 1 of the service) and whether they were readmitted 
within 90 days. All patients who had died before 90 days 
after the notification had been sent were removed from 
this analysis, in line with literature,17 18 as these deaths 
could skew the results (eg, if a patient died within 90 days 
without readmission, they would be recorded as ‘no read-
mission within 90 days’, which would be an inappropriate 
classification).
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Table 2 Number of patients offered a DMR service who 
did not die (n=1844) and went on to receive the service, by 
whether there was a hospital readmission within 90 days of 
discharge
Patient group
Readmission 
within 90 days
n (%)
No 
admission 
within 90 
days
n (%)
Total
n (%)
DMR started 307 (31.4) 366 (42.2) 673 (36.5)
No DMR 670 (68.6) 501 (57.8) 1171 (63.5)
Total 977 867 1844
DMR, discharge medicines review.
A conditional inference tree (CTree) was produced to 
look at which patient traits had the strongest association 
with whether a patient was readmitted within 90 days. 
CTrees partition cohorts by selecting successive splits in 
variables with the strongest association to the outcome 
of interest, as measured by p values, and have previously 
been used in health service research.19 20 CTree is a non- 
parametric class of regression trees embedding tree- 
structured regression models into a well- defined theory 
of conditional inference procedures; it uses a statistical 
theory (selection by permutation- based significance 
tests) in order to select variables instead of selecting the 
variable that maximises an information measure (Gini 
coefficient or information gain) and thereby removes 
the potential bias in Classification and Regression Trees 
(CART) or similar decision trees.21 In this case, the CTree 
used gender, deprivation decile, age decile, diagnosis 
grouping (eg, respiratory, circulatory) and whether a 
DMR had been started to look at the relationship of these 
with readmission within 90 days. A significance level of 
0.05 was used.
To better understand the probability of readmission 
over time, the Kaplan- Meier estimator was used to esti-
mate the likelihood of readmission for a patient who had 
started a DMR versus a patient who had not been provided 
a DMR over specified time intervals. The inverse of the 
Kaplan- Meier curve was created to describe the likeli-
hood of readmission, based on avoidance of readmission.
A Schoenfeld residual test for non- proportional hazards 
was used to test the proportional hazards assumption.22 
To adjust for the findings of this test, we created a time 
stratified Cox regression survival analysis using age, sex, 
diagnosis, deprivation and DMR as variables. We used a 
step function (time- dependent coefficient) model, using 
a stratification time we chose based on a plot of the Aalen 
model.23 We have looked at the HR confidence inter-
vals to combat the possible issues with type 1 error and 
to better estimate the association between DMR use and 
readmission.
The Strengthening the Reporting of Observational 
Studies in Epidemiology checklist for cohort studies was 
used to guide the reporting of this study and is shown in 
online supplementary table 2.
Patient involvement
Patients were not involved in the design or conduct of 
this study.
reSultS
A total of 1923 records were available within the specified 
time period (February 2017–April 2018), up to 90 days 
prior to the last date in the data extract available. There 
was a small number of cases where some data were not 
recorded in the system (36 patients with blank diagnosis, 
1 with missing deprivation quintile). These have been 
removed for all analyses except for Kaplan- Meier.
Primary outcome
A total of 244 records referred to patients who died within 
90 days of a notification being sent; 79 of these patients 
died prior to any readmission. In order to eliminate any 
skew caused by patients who were not readmitted but died, 
the 79 records were removed for all χ2 and conditional 
inference analyses. Therefore, a total of 1844 records 
were used, with 673 (36.5%) of those records referring 
to patients receiving the DMR service, representing the 
intervention cohort.
A statistically significant difference was identified at the 
90- day readmission rate of those patients who had started 
a DMR and those who had not received a DMR (Pearson’s 
χ2=23.0829) (p<0.001). This implies there was an associa-
tion between when a DMR had been started and readmis-
sion within 90 days, and based on the rates of readmission 
we conclude that readmission was less likely (table 2). 
The characteristics of the baseline population of the 
study (n=1923), split into groups in relation to whether 
they had received DMR part 1 service on discharge from 
hospital, are presented in online supplementary table 3.
The CTree used to identify the variable with the stron-
gest association to readmission within 90 days used age 
decile, sex, deprivation decile, diagnostic grouping and 
DMR type (started or not started) as the possible criteria 
for classification. This identified that the variable with the 
strongest association was whether the patient had started 
a DMR or not (p<0.001) (online supplementary figure 1). 
Just over 40% of those who had started a DMR were read-
mitted within 90 days, compared with just under 60% of 
those who did not have a DMR. Among those who had 
started a DMR, the next statistically significant association 
was age (p~0.035). Those in the 20–29, 40–49, 50–59 and 
60–69 age brackets had a readmission rate within 90 days 
of just over 30%, whereas other ages had a readmission 
rate within 90 days of around 50%. If a DMR had not been 
started, gender was the factor with the next strongest asso-
ciation with readmission within 90 days (p<0.001).
To further investigate this, the inverse of the Kaplan- 
Meier estimator was produced by completing survival 
analysis (with patients who died acting as censored 
data) and demonstrated that the patient group who had 
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Figure 2 Survival analysis looking at the probability of 
readmission postdischarge for patients who had started a 
discharge medicines review (DMR) service compared with 
those who had not, over time.
received a DMR had a lower hospital readmission rate 
at 30 (22% vs 36 %), 60 (36% vs 49%) and 90 (45% vs 
56%) days postdischarge, as illustrated in the inverse of 
the Kaplan- Meier curve in figure 2.
To build on this survival analysis, a time stratified Cox 
survival analysis was used with a stratification of the DMR 
variable at 40 days, identified by plotting DMR using the 
Aalen model. The only variable triggering the signif-
icance tests when we ran the survival analysis was the 
stratified DMR variable from 0 to 40 days. This variable 
had an HR of 0.59739 with a CI underneath 1 (0.5043 to 
0.7076). This suggests that readmission within 40 days is 
less likely when a DMR has been started. Online supple-
mentary table 4 presents the full results on p values for 
each variable.
Secondary outcomes
The CTree suggested that sex may also be associated 
with reduction of readmission within 90 days for patients 
without a DMR. However, the results of the Cox survival 
analysis showed no significant associations other than 
with DMR, with HRs that do not show any consistent 
effect from any of the other variables (online supple-
mentary table 5). This could indicate that further tests 
should be done to model processes for patients who have 
started a DMR and those with no DMR separately when 
more data are available in order to understand where this 
discrepancy comes from.
DISCuSSIOn
This is the first published study, to our knowledge, using 
a range of national databases to link routine service 
activity and patient data from community pharmacy and 
hospital, at a national level, to investigate the association 
with hospital readmissions. The analysis of the linked 
data has facilitated three methods for checking whether 
the DMR intervention had an association with readmis-
sion. This process has demonstrated that those patients 
who had started a DMR were significantly less likely to be 
readmitted within 90 days than those who had no DMR 
provision. The DMR intervention was also found to be the 
factor most associated with reduced readmissions within 
40 days when conducting multivariate survival analysis 
to better estimate the independent association between 
DMR and readmission.
Results from this study support published literature 
that community pharmacist postdischarge interven-
tions have positive outcomes on patient care. In a recent 
systematic review looking at pharmacist- led medication 
reconciliation at patient discharge, only 30% of the 
studies described a patient discharge plan, and in only 
14% of cases information of the patient’s medication 
was shared with community pharmacists.24 The DMR 
service provides a structured approach to information 
sharing, overcoming the major organisational- level and 
individual- level factors affecting the medication recon-
ciliation process,25 and an opportunity for a face- to- face 
discussion and counselling with the patient to account for 
their changing needs postdischarge. Literature reports 
that patients’ information needs are individual, and even 
when counselled by hospital pharmacists only half of the 
patients could recall information related to medication 
changes.26 Unlike other systems in the UK, the DMR 
service is available nationally across Wales, and from April 
2020 a new functionality will become available in the 
system, so that outcome data completed by community 
pharmacists will be available to view in the hospital where 
the referral was generated.
We have found that the DMR service has a more prom-
inent association with patient readmission rates than 
reported in previous work. This contributes to the body of 
evidence around community pharmacy services or inter-
ventions that may reduce hospital readmissions, thereby 
supporting delivery of government initiatives to promote 
the Care Closer to Home agenda.27 The role of commu-
nity pharmacists in seamless primary care services has 
been recognised in the Strategic Programme for Primary 
Care and with the Welsh Government having recently 
announced their support to community pharmacists 
and committed financially to a sustainable, appropriately 
trained workforce to deliver extended services.28–30
The primary outcome data align well with that previ-
ously published in the North East England transfer- of- care 
service,8 9 which also demonstrated a significant decrease 
in readmissions for patients receiving postdischarge 
community pharmacy care. Both studies share the limita-
tion that the data linkage fails to record patients’ access 
of any other healthcare services, such as the GP, following 
discharge, which exists as a potential confounder to the 
results. This means that findings presented here, similar 
to those of Nazar et al,8 9 are that of correlation rather 
than a direct casual consequence.
Another recent study adopting consensus methodology 
aimed to identify appropriate referral criteria of inpatients 
to be offered this type of follow- up care. Age was not a 
factor rated most highly by expert panel members (ie, top 
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3); however, it was recognised as a potential parameter to 
consider.13 31 Our findings infer that patients aged 50–79 
years fare best in terms of reduced hospital readmissions 
when offered the DMR service; however, the small numbers 
of patients across all age groupings limit the validity of 
this deduction. The debate around the targeting of these 
types of postdischarge services is therefore still warranted 
to understand which patients benefit most significantly 
towards optimising service efficiency and effectiveness.
The process of data linking depicted here illustrates the 
complexity in the information technology (IT) health-
care system, which poses challenges for health service 
providers, commissioners, evaluators and researchers. 
Work commissioned by the King’s Fund recently reported 
that the key contributing barriers to the provision of clin-
ical services within community pharmacies in the UK are 
isolation from the central healthcare system and lack of 
digital interoperability.14 32 The Minister for Health and 
Social Services in Wales has set the plans to develop a 
National Data Resource (NDR) as part of a ‘Statement 
of Intent’ to better use health and care data in October 
2017. It aims to deliver linked, longitudinal data for both 
direct patient care and healthcare analysis and research. 
NDR will drive forward the interoperability of health 
and care systems, ultimately delivering benefit across the 
healthcare economy to patients, clinicians, operational 
managers and policy makers.
Within England, there has been much attention in the 
past decade on shared electronic patient records, the 
Summary Care Record (SCR). This was introduced in 2009 
as part of the National Programme for IT by the Department 
of Health to provide a mechanism to improve communica-
tion and connectedness between many healthcare sectors 
of the NHS. The sharing of such a record aims to facilitate 
safe, appropriate and tailored care provision for patients 
from wherever they may be accessing it.31 33 An indepen-
dent evaluation in 2010 raised a number of concerns about 
complexity, technical challenges, workload and informa-
tion governance. This has also been accompanied by slower 
than anticipated uptake and faced controversy, both in the 
public and professional arenas.32 34 Recently, announce-
ments have been made that the SCR will be phased out by 
2024 and will be replaced with local health and care records 
that will combine GP, hospitals, and other health and social 
care information.33 35 The data will be anonymised within 
the NHS and therefore facilitate evaluation and research. 
This proposal is a development towards improving evidence- 
based practice, which requires appropriate and supportive 
informatics infrastructure. Bakken36 contests that evidence 
to underpin clinical practice should be broadly conceptu-
alised as a continuum of synthesised information, ranging 
from the ‘gold standard’ of randomised controlled trails, 
to aggregated data from individual practice of a clinician 
or experiences of individual patients. In establishing an 
integrated, longitudinal patient care record, evidence- 
based practice will be facilitated by the building of evidence 
from clinical practice and its outcomes.34 However, in the 
interim, SCR uptake and access have been patchy, with little 
published evidence of facilitating evaluation and research 
agendas to investigate health outcomes as a consequence 
of interventions.
This was a pragmatic observational cohort study, with 
enrolment into the DMR based on clinician judge-
ment, and as such no power calculation could have 
been performed and there was a large potential for 
bias. However, we tried to estimate the effect size using 
HR in the survival analysis and we addressed this bias as 
far as possible with confounder adjusted analysis and by 
exploring the possibility of residual confounding.
Although we have tried to take into account some 
socioeconomic indicators (i.e. deprivation decile), we 
have not investigated whether those who have started a 
DMR are more health conscious than those who are not, 
so some of the effect seen here may be indicative of some 
patient activation or other related external factors, as yet 
unmeasured. Barriers to community pharmacists under-
taking follow- up reviews postdischarge have recently been 
reported in the literature. Elson et al37 explored patients’ 
knowledge of new medicines after discharge from 
hospital and identified that fewer than half of the patients 
who were allocated to receive a community pharmacy 
medicines review received one. Further work will involve 
exploring factors that support or inhibit activation of part 
1 of the DMR via an implementation science lens.
COnCluSIOn
Evidence supporting systems that identify and enact on 
unintended discrepancies after patient discharge from 
hospital is already widely available; this study demon-
strates that the DMR service has a more prominent asso-
ciation with patient readmission rates than reported in 
previous work. This adds to the body of evidence that 
continuity of care on discharge and transfer of care 
should be prioritised as a global patient safety challenge, 
to achieve a 50% reduction in minimising medication 
safety issues, stated as a target in a recent WHO report on 
tackling medication- related harm.38
Despite the current challenging nature of linking NHS 
data collected across a range of organisations, it is possible 
to use linked data effectively to not only improve conti-
nuity and coherency of care, but also to facilitate service 
optimisation, evaluation and evidenced- based practice.
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